吉林省輝南長龍生化藥業股份有限公司

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8049)

DISCLOSEABLE TRANSACTIONS
SUBSCRIPTION OF STRUCTURED DEPOSIT PRODUCTS

The Board of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the "**Company**") is pleased to announce that on 28 August 2026, the Company subscribed for the structured deposit product from Bank of China ("**BOC**") in the amount of RMB30,000,000.

IMPLICATIONS UNDER THE LISTING RULES

As the applicable percentage ratios in respect of the BOC subscription, on an aggregated basis pursuant to Rule 19.22 of the GEM Listing Rules, exceed 5% but are less than 25%, the BOC subscriptions constitute discloseable transactions under Chapter 19 of the GEM Listing Rules and are therefore subject to the reporting and announcement requirements under Chapter 19 of the GEM Listing Rules, but is exempted from the compliance of the Shareholder's approval requirement.

The BOC subscriptions

Further details regarding the terms of the BOC structured deposit product are as follows:

BOC Structured Deposit Product "中國銀行人民幣結構性存款產品"

Date of subscription:	28 August 2026
Subscription amount:	RMB30,000,000
Type of return:	Principal-guaranteed with floating return
Term of investment:	182 Days
Expected annualized return rate:	3%
Risk level of product (internal risk rating by the bank):	Low
Right of early termination or redemption:	The Subscriber does not have the right of early termination or redemption
Balance as at the date of this announcement:	RMB30 million

On 28 August 2026, the Company purchased the BOC structured deposit products on an aggregated basis with a principal amount of RMB80 million. Pursuant to Rule 19.22 of the GEM Listing Rules, as at least one of the applicable percentage ratios of such purchase, when aggregated with the outstanding balance of the investment and structured deposit product, exceeded 5% but was less than 25%, such aggregated purchase constituted a discloseable transaction which was subject to reporting and announcement requirements under Chapter 19 of the GEM Listing Rules.

INFORMATION ON THE PARTIES

The Company is principally engaged in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC under the brand names of Changlong (長龍) and Qing Tong (清通). BOC is a licensed bank established under the laws of the PRC, which is principally engaged in the provision of corporate and personal banking and other financial services in the PRC. To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, BOC and their respective ultimate beneficial owners are third parties independent of the Company and its connected persons.

REASONS FOR AND BENEFITS OF THE SUBSCRIPTIONS

The subscriptions were carried out by the Company for treasury management purpose in order to maximize the utilization of its surplus cash received from its business operations, with a view to achieving balanced yields whilst maintaining high liquidity and a low level of risks. Taking into account of, among others, the low level of risks and the expected rates of return, the Company considers that the subscriptions will provide the Group with better returns than the returns on deposits generally offered by commercial banks and increase the Company's overall earnings in the long run. The Company will monitor and manage the subscriptions more closely and effectively.

As at the date of this announcement, the Company did not experience any losses on the structured deposit products. Further, the subscriptions were funded by the surplus cash of the Company , therefore they would not affect the working capital or the operation of the Company. As such, the Directors are of the view that the subscriptions are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

IMPLICATIONS UNDER THE LISTING RULES

As the applicable percentage ratios in respect of the subscriptions, on an aggregated basis pursuant to Rule 19.22 of the GEM Listing Rules, exceed 5% but are less than 25%, the BOC subscriptions constitute discloseable transactions under Chapter 19 of the GEM Listing Rules and are therefore subject to the reporting and announcement requirements under Chapter 19 of the GEM Listing Rules, but is exempted from the compliance of the Shareholder's approval requirement.

By order of the Board
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
Zhang Yi
Chairman

Tonghua, Jilin Province, the PRC

28 August 2026

As at the date of this announcement, the Board comprises five executive directors, being Zhang Yi, Xu Xiang Fu, Wang Wei, Chi Chun Hong and Li Ning; and three independent non-executive directors, being Gao Qi Pin, Bai Jun Gui and Tian Jie.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the "Latest Listed Company Announcements" page on the Stock Exchange's website at www.hkexnews.hk for at least 7 days from the date of its posting.